A practical reference on research chemical: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-03-16 and is reviewed periodically as new material appears.
Laboratory detection of GW501516 commonly uses liquid chromatography coupled with tandem mass spectrometry. The method can identify the parent compound or its metabolites in urine and blood after sample cleanup. Protein precipitation, solid-phase extraction, or enzymatic hydrolysis may precede analysis, depending on the matrix. Reference standards are required for accurate quantification and confirmation. Because the compound is not approved, testing often occurs in anti-doping, forensic, or research settings rather than routine clinical care. Results are reported with limits of detection and quantification.
Stability of GW501516 depends on form, temperature, light exposure, and moisture. Solid reference material is typically stored frozen or refrigerated in a desiccator and protected from light. Solutions in organic solvents such as dimethyl sulfoxide are often kept frozen in aliquots to reduce freeze-thaw cycling. Aqueous solubility is low, so aqueous stock solutions can be difficult to prepare without cosolvents. Degradation may appear as changes in chromatographic purity or mass spectral signal. Stability studies are needed to establish shelf life for any specific preparation.
Quality assessment for cardarine samples usually combines identity, purity, and impurity testing. Nuclear magnetic resonance spectroscopy and mass spectrometry can confirm molecular structure, while high-performance liquid chromatography estimates purity. Certificates of analysis from testing laboratories may list these results, but they do not establish safety or legality. In the absence of approved manufacturing, products sold online may contain the wrong compound, variable amounts, or unlisted contaminants. Independent verification is therefore central to analytical work and to interpreting any reported biological activity.
Cardarine is a synthetic compound also known as GW501516, GW-501516, and sometimes endurobol. It was developed as a selective agonist of peroxisome proliferator-activated receptor delta, a nuclear receptor involved in fatty acid oxidation and energy metabolism. The compound was studied in preclinical models for metabolic and cardiovascular conditions, but it did not become a marketed human medicine. In regulatory and anti-doping contexts, it is treated as a prohibited substance rather than a licensed medicine.
The pharmacological interest in cardarine centers on PPARδ activation and its downstream effects on lipid handling and mitochondrial function. In animal studies, PPARδ agonists have been associated with changes in exercise endurance and fatty acid utilization, though results vary by model and protocol. Human data remain sparse, and the absence of large controlled trials limits conclusions about efficacy. Researchers often describe the compound as a tool for probing PPARδ biology rather than a proven therapeutic agent.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Common for reference-grade material. |
| Solubility | Low in water | Dissolves in DMSO and some organic solvents. |
| Typical storage | -20 °C, desiccated | Protect from light and moisture. |
| Analytical method | LC-MS/MS | Used for trace detection in biological matrices. |
| Purity assessment | HPLC with UV detection | Often combined with NMR and mass spectrometry. |
At the molecular level, GW501516 binds and activates PPARδ, a nuclear receptor that regulates transcription. Activation shifts expression of genes involved in fatty acid oxidation, energy expenditure, and lipid transport in skeletal muscle and liver. Animal studies report increased endurance and altered lipid profiles after exposure. Human data are limited to small trials and do not establish long-term safety or efficacy. PPARδ also has roles in cell proliferation, so the relationship between activation and cancer risk remains an open question.
Published literature on cardarine includes in vitro assays, rodent experiments, and a small number of human studies. Reports describe effects on exercise capacity and lipid metabolism in animals, while human evidence is sparse. Many online descriptions present the compound as a proven endurance aid, a claim not supported by regulatory approval or large clinical trials. Analytical studies focus on identifying the parent compound and its metabolites in biological samples. Important uncertainties include species differences, dose-response relationships, and the relevance of rodent tumor findings to humans.
Cardarine is a common name for GW501516, a synthetic compound first described in the 1990s as a selective agonist of the peroxisome proliferator-activated receptor delta. It was studied in preclinical models for metabolic and cardiovascular conditions, but it has not been approved as a medicine in the United States, Europe, or other major jurisdictions. Retail products labeled as cardarine are generally research chemicals or supplements, not pharmaceutical formulations. Because human safety and efficacy data remain limited, regulatory agencies treat it as an unapproved substance rather than a therapeutic product.
Sporting authorities added GW501516 to prohibited lists after it appeared in athlete samples and online markets. The World Anti-Doping Agency classifies it as a hormone and metabolic modulator, and its use can lead to an anti-doping rule violation. Some early laboratory work suggested effects on fatty acid oxidation and endurance-related metabolism in animals, but those findings do not establish safe or effective use in people. Reports of adverse events in humans are scarce and often anecdotal, which complicates risk assessment.
Legal status varies by country. In some places, cardarine is controlled under medicines or psychoactive substances laws; in others, it may be sold with minimal oversight as a research chemical. Customs agencies have intercepted shipments, and several national health agencies have issued warnings about products marketed for bodybuilding or performance enhancement. The lack of a standardized pharmaceutical supply means identity, purity, and contamination levels can differ widely between samples. These factors make cardarine a regulatory and public health concern rather than a conventional prescription drug.
Cardarine can be detected in biological samples and product materials using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The method separates compounds by chromatography and identifies them by mass-to-charge transitions, allowing low-level detection in urine or blood. Sample preparation often involves enzymatic hydrolysis, solid-phase extraction, or protein precipitation. Certified reference materials and isotope-labeled internal standards improve quantification. Detection windows depend on metabolism, matrix, and assay sensitivity, so no single universal window applies.
Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.
Because cardarine is not an approved medicine, no pharmacopeial monograph defines its identity, purity, or storage requirements. Laboratories typically rely on in-house methods and reference standards when testing materials labeled as GW501516. Certificates of analysis may report purity and identity for a specific batch, but their scope varies and they do not guarantee safety or legal status. Independent verification can include high-performance liquid chromatography, mass spectrometry, nuclear magnetic resonance, and elemental analysis. The distinction between research chemical labeling and human use is significant because quality standards and oversight differ.
== History == This method was developed by Solomon Berson and Rosalyn Sussman Yalow at the Veterans Administration Hospital in the Bronx, New York. This revolutionary development earned Dr. Yalow the Nobel Prize for Medicine in 1977, the second woman ever to win it. In her acceptance speech, Dr. Yalow said, "The world cannot afford the loss of the talents of half its people if we are to solve the many problems which beset us." Yalow shared the Nobel Prize with Roger Guillemin, and Andrew Schally who earned the prize based on their research into "the peptide hormone production of the brain".
== Awards and recognition == Jimmy John's was named number one on the Entrepreneur 2016 Franchise 500. In 2014, YouGov BrandIndex ranked restaurant chains that have the highest millennial brand loyalty, and Jimmy John's topped the ranking with 83% of the vote based on restaurants they would consider going to again. Jimmy John's was named the #2 Most Popular Restaurant for Business Meals by expense reporting program Certify. In 2015, Entrepreneur.com named Jimmy John's one of the 10 Promising Franchises for Ambitious Entrepreneurs. In March 2017, Jimmy John's won Franchise Times' "Deal of the Year" for attracting Roark Capital Group as the company's new majority owner. FT's judges called the deal "one of the best private equity deals of all time in the restaurant business." In 2011 CNN Money listed Jimmy John's as one of ten "Great Franchise Bets". The company estimates that annual sales can be as high as $1.2 million while net profits can average at about $280,000. Real estate start-up costs are estimated to be between $305,000 and $485,500.
== Pathophysiology == As of 2026, the pathophysiology of fibromyalgia had not yet been elucidated. The prevailing view was that the fibromyalgia resulted from an amplification of pain by the central nervous system, but other hypotheses have also been suggested.
Sources: en.wikipedia.org
== Personal life == Vaghela was born to Laxmansinh and Nathuba on 21 July 1940 in Vasan in Gandhinagar district, in Gujarat. He completed Master of Arts in economics from Gujarat University. Vaghela married Gulab Ba on 9 June 1960, with whom he has three sons. His son Mahendrasinh was MLA from Bayad from 2012 to 2017.
An exclusive license outside of South Korea and China with Sanofi for Hanmi's Glucagon-like peptide-1 receptor agonist drug candidates for diabetes; Sanofi paid $434 million upfront and up to $3.2 billion in milestones and royalties over 10%. The deal included efpeglenatide, a long-acting glucagon-like peptide-1 receptor agonist; an insulin intended to be delivered once per week, and a fixed-dosed weekly GLP1-RA/insulin drug combination. An exclusive license outside of South Korea and China with the J&J subsidiary Janssen Pharmaceuticals for Hanmi's oxyntomodulin-analog metabolic disease programs, including HM12525A; J&J paid $105 million upfront and the deal included $810M in milestones and royalties higher than 10% An exclusive license in China with the Chinese company ZAI Labs for olmutinib. In April 2016 Hanmi announced that it had acquired land near Yantai in the Shandong province of China, where it would build a manufacturing plant and R&D facility; at that time it already had a facility in Beijing. In July Hanmi said it intended to invest more heavily in developing candidate substances of promising new drugs at an early stage in new pharmaceutical and biotech related fields, including through a venture capital firm set up by Sung-ki and colleagues. In May 2016 the Korean regulatory authority approved olmutinib as a second-line treatment for certain kinds of non-small cell lung cancer.
=== Parkinson's disease === In the case of Parkinson's disease, a series of observational studies that consistently suggest a possibly substantial reduction in risk among smokers (and other consumers of tobacco products) has led to longstanding interest among epidemiologists. Non-biological factors that may contribute to such observations include reverse causality (whereby prodromal symptoms of Parkinson's disease may lead some smokers to quit before diagnosis), and personality considerations (people predisposed to Parkinson's disease tend to be relatively risk-averse, and may be less likely to have a history of smoking). Possible existence of a biological effect is supported by a few studies that involved low levels of exposure to nicotine without any active smoking. Another study considered a possible role of nicotine in reducing Parkinson's risk: nicotine stimulates the dopaminergic system of the brain, which is damaged in Parkinson's disease, while other compounds in tobacco smoke inhibit MAO-B, an enzyme which produces oxidative radicals by breaking down dopamine. A data-driven hypothesis that long-term administration of very low doses of nicotine (for example, in an ordinary diet) might provide a degree of neurological protection against Parkinson's disease remains open as a potential preventive strategy.
=== Hemoglobin synthesis and function === PLP aids in the synthesis of hemoglobin, by serving as a coenzyme for the enzyme aminolevulinic acid synthase. It also binds to two sites on hemoglobin to enhance the oxygen binding of hemoglobin.
Sources: en.wikipedia.org
Alternative splicing of intron 9 creates the β and γ isoforms with altered C-termini. An internal promoter in intron 4 produces the ∆133 and ∆160 isoforms, which lack part of the TAD and DBD. Alternative translation initiation at codons 40 or 160 results in ∆40p53 and ∆160p53 isoforms, respectively.
Fluorinated surfactants or fluorosurfactants are a subgroup of PFAS characterized by a hydrophobic fluorinated "tail" and a hydrophilic "head" that behave as surfactants. These are more effective at reducing the surface tension of water than comparable hydrocarbon surfactants. Fluorosurfactants tend to concentrate at the phase interfaces. Fluorocarbons are both lipophobic and hydrophobic, repelling both oil and water. Their lipophobicity results from the relative lack of London dispersion forces compared to hydrocarbons, a consequence of fluorine's large electronegativity and small bond length, which reduce the polarizability of the surfactants' fluorinated molecular surface. Fluorosurfactants are more stable than hydrocarbon surfactants due to the stability of the carbon–fluorine bond. Perfluorinated surfactants persist in the environment for the same reason. Fluorosurfactants such as PFOS, PFOA, and perfluorononanoic acid (PFNA) have caught the attention of regulatory agencies because of their persistence, toxicity, and widespread occurrence in the blood of general populations.
=== 20 May === Russia claimed to have taken the village of Bilohorivka, Luhansk Oblast. Two people were killed in Russian attacks in Kherson and Zaporizhzhia Oblast. Ukrainian missiles hit a Russian military facility near Katerynivka, Luhansk Oblast, causing "powerful" explosions and a fire. The Ukrainians claimed to have killed 13 Russian servicemen in the strike, while 26 others were wounded. One of the wounded was allegedly Colonel General Gennadiy Anashkin, commander of Russia's Southern Military District. Deputy Governor of Kharkiv Oblast Roman Semenukha claimed that Ukraine still controls 60% of Vovchansk. A Russian court sentenced 24-year-old Ilya Baburin to 25 years in prison for treason and plotting an arson attack against a recruitment center in Siberia on behalf of Ukraine and setting fire to a local music school.
Sources: en.wikipedia.org
LC-MS/MS is common, often after sample cleanup. The assay targets GW501516 or its metabolites.
Reference material is usually kept cold, dry, and protected from light. Frozen aliquots reduce repeated freeze-thaw cycles.
No approved pharmaceutical product exists, so manufacturing and quality controls are not standardized. Products may contain different compounds or impurities.
Cardarine is an investigational synthetic compound that acts as a PPARδ agonist. It is also known as GW501516 and has been studied mainly in preclinical research. It is not an approved medicine.